Issues: Vax Specific

Anthrax

Hepatitis B

Hib 

HPV

Influenza

Lyme Disease
Meningococcal

MMR    

Pneumococcal

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Religion

Thimerosal

 

Vaccine Info

2014 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

PNEUMOCOCCAL VACCINE

FDA expands use of Prevnar 13 to include ages 6-17 years; now approved for ages 6 weeks - 17 years (before 18th birthday) and 50 years and older.  (01-25-13) FDA approval letter | current package insert

Podcast: Prevent Pneumonia
Dr. Kathleen Dooling with the CDC explains what pneumonia is, its symptoms, and how to prevent it. [Released 5/23/2012; Run time 4:50]

FDA expands use of Prevnar 13 vaccine for people ages 50 and older
Link to Press Announcement  (12-30-11)

CDC report summarizing data on the immunogenicity and safety of PCV13 in adults and outlining key additional evidence requested by ACIP to formulate recommendations for its use.  MMWR 2012;61(21):394.  (6-1-12)

Pneumococcal Conjugate (PCV13) Vaccine Information Statements:

Pneumococcal Polysaccharide (PPSV23) Vaccine Information Statements :  

 

This page was last updated on February 12, 2014

2014 Institute for Vaccine Safety